213 Users Online
Crystal-Induced Arthritides Treatment Market Segmented By Drug Type such as Nonsteroidal anti-inflammatory drugs (NSAIDs), Disease-modifying Antirheumatic drugs (DMARDs, Corticosteroids, Allopurinol, Pegloticase
Arthritis is a very common disease. However, it is not well understood. Arthritis is an inflammatory condition that causes inflammation of joints. Depending on a person’s age, sex and race, there are more than 100 types of arthritis. Crystal-Induced Arthritides involving crystal deposition in the articular and periarticular soft tissue with resultant inflammation.
Crystal-induced Arthritides remains a common cause of monoarthritis, oligoarthritis, and polyarthritis, most common crystal-induced Arthritides are Gout and pseudogout and both are caused by monosodium urate monohydrate crystals and calcium pyrophosphate crystal respectively.
Symptoms such as intense joint pain, red or purple skin around the join, the swollen joint that's warm to the touch, swelling, loss of appetite, rash, and fever are being observed. Despite the sudden onset and intense pain, Crystal-Induced Arthritides attacks usually peak and resolve within a week or 10 days and then disappear completely. Excess formation of inorganic pyrophosphate, cartilage matrix abnormalities, the presence of articular cartilage vesicles and other changes occur with Crystal-Induced Arthritides disease.
Increasing the prevalence rate of Crystal-Induced Arthritides such as monoarthritis, oligoarthritis, polyarthritis, and Gout and pseudogout are the primary factors driving the growth of the Crystal-Induced Arthritides Treatment market throughout the globe.
Some key factors such as increasing awareness of Crystal-Induced Arthritides disease and patient education program that are directed by government and companies for better knowledge about these diseases is likely to drive the growth of Crystal-Induced Arthritides treatment market.
However, Crystal-Induced Arthritides Diagnosing is too difficult but accurate diagnosis requires synovial fluid analysis. Due to its increasing high demand and offers the best chance of curing the disease, Crystal-Induced Arthritides treatment market is expected to grow for the forecast period. Moreover, high treatment cost of Crystal-Induced Arthritides, which makes it unaffordable for some people, might deter the development of Crystal-Induced Arthritides market to some extent.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
| Drug Type |
|
| route of administration |
|
| Distribution Channel |
|
| Region |
|
Rapidly increasing prevalence rate of Crystal-Induced Arthritides is the major driver in the Crystal-Induced Arthritides treatment market. Prevalence of disease increases with age. The global Crystal-Induced Arthritides treatment market by Drug type is expected to be dominated by the Nonsteroidal anti-inflammatory drugs and Disease-modifying Antirheumatic drugs, the cause of higher adoption by patients for Crystal-Induced Arthritides treatments.
Allopurinol was documented as the most frequently used gout medication in 65% of the subjects, By Distribution channel, Crystal-Induced Arthritides market is expected to be dominated by Hospital Pharmacies and retail pharmacies are dominating segments and hold a maximum share of global Crystal-Induced Arthritides treatment market on the basis of the end user. The manufacturers in the Crystal-Induced Arthritides market are focusing on manufacturing advanced technology for better patient compliance and make the procedure easier.
In terms of regional and geographical perspective, the global Crystal-Induced Arthritides market is described into five key regions: North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. In terms of revenue, North America is expected to account for the largest share in the forecast period in the Crystal-Induced Arthritides market due to rising awareness about arthritic conditions. North America followed by Western Europe and Japan in the concerned market.
Europe is expected to be the second leading regions in terms of revenue in the Crystal-Induced Arthritides market over the forecast period due to the high prevalence of chronic disease and improving healthcare infrastructure. The Middle East & Africa and Latin America are expected to register moderate growth because of lack of awareness and less investment spent on healthcare and research.
Examples of some of the market participants in the global Crystal-Induced Arthritides market identified are: Johnson & Johnson Services, Inc., Zydus Cadila, Takeda Pharmaceutical Company Limited, Genentech, Inc., Latona Life Sciences, Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline plc, Savient Pharmaceuticals, Inc,., and others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Sales Team
Client Partner
